United Therapeutics (NASDAQ:UTHR) Upgraded at StockNews.com

StockNews.com upgraded shares of United Therapeutics (NASDAQ:UTHRFree Report) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday.

UTHR has been the topic of a number of other reports. Oppenheimer raised their price target on United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a report on Thursday, May 2nd. Wedbush reissued an outperform rating and set a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. The Goldman Sachs Group raised their price target on United Therapeutics from $218.00 to $240.00 and gave the company a neutral rating in a report on Friday, May 3rd. JPMorgan Chase & Co. raised their price target on United Therapeutics from $280.00 to $300.00 and gave the company an overweight rating in a report on Tuesday, May 21st. Finally, HC Wainwright reissued a buy rating and set a $300.00 price target on shares of United Therapeutics in a report on Thursday, May 2nd. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of Buy and a consensus price target of $312.22.

Get Our Latest Stock Analysis on United Therapeutics

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $288.06 on Wednesday. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $288.83. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The business’s fifty day moving average price is $258.33 and its two-hundred day moving average price is $238.59. The firm has a market capitalization of $12.78 billion, a PE ratio of 13.62, a P/E/G ratio of 4.19 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHRGet Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same period last year, the company earned $4.86 earnings per share. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. On average, research analysts expect that United Therapeutics will post 24.61 EPS for the current year.

Insider Buying and Selling

In related news, Director Christopher Causey sold 2,000 shares of United Therapeutics stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $281.53, for a total transaction of $563,060.00. Following the transaction, the director now directly owns 4,185 shares of the company’s stock, valued at $1,178,203.05. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Christopher Causey sold 2,000 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $281.53, for a total value of $563,060.00. Following the completion of the transaction, the director now owns 4,185 shares in the company, valued at approximately $1,178,203.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $281.19, for a total value of $1,012,284.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $36,554.70. The disclosure for this sale can be found here. Insiders have sold a total of 177,128 shares of company stock valued at $43,561,905 over the last three months. Company insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jump Financial LLC acquired a new stake in United Therapeutics during the 3rd quarter worth about $251,000. J.P. Morgan Private Wealth Advisors LLC boosted its position in United Therapeutics by 6.1% during the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 73 shares during the period. Janney Montgomery Scott LLC boosted its position in United Therapeutics by 17.0% during the 3rd quarter. Janney Montgomery Scott LLC now owns 8,809 shares of the biotechnology company’s stock worth $1,990,000 after acquiring an additional 1,279 shares during the period. Van ECK Associates Corp boosted its position in United Therapeutics by 0.9% during the 3rd quarter. Van ECK Associates Corp now owns 9,685 shares of the biotechnology company’s stock worth $2,188,000 after acquiring an additional 84 shares during the period. Finally, Pathstone Family Office LLC acquired a new stake in United Therapeutics during the 3rd quarter worth about $369,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.